Our current understanding of and approach to the management of lung cancer with pulmonary hypertension

Dauriat, Gaëlle; Lepavec, J.; Pradère, Pauline; Savale, Laurent; Fabre, Dominique; Fadel, Élie

doi:10.1080/17476348.2021.1842202

Cited by 3 publications

(2 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the early prevention and variety of lung cancer therapy, the therapeutic effect for lung cancer patients has significantly improved [3]. A few studies have reported that lung cancer patients tend to develop symptoms of dyspnea, parenchymal AGING disease, or left heart disease with pulmonary hypertension (PH), which affects their quality of life [4,5].…”

Section: Introductionmentioning

confidence: 99%

G6PD is a prognostic biomarker correlated with immune infiltrates in lung adenocarcinoma and pulmonary arterial hypertension

Ding,

Sang,

et al. 2024

Aging

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD) with Pulmonary arterial hypertension (PAH) shows a poor prognosis. Detecting related genes is imperative for prognosis prediction. Methods: The gene expression profiles of LUAD and PAH were acquired from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database, respectively. The co-expression modules associated with LUAD and PAH were evaluated using the Weighted Gene Co-Expression Network Analysis (WGCNA). The relationship between key gene expression with immune-cell infiltration and the tumor immune microenvironment (TIME) was evaluated. We confirmed the mRNA and protein levels in vivo and vitro. G6PD knockdown was used to conduct the colony formation assay, transwell invasion assay, and scratch wound assay of A549 cells. EDU staining and CCK8 assay were performed on G6PD knockdown HPASMCs. We identified therapeutic drug molecules and performed molecular docking between the key gene and small drug molecules. Results: Three major modules and 52 overlapped genes were recognized in LUAD and PAH. We identified the key gene G6PD, which was significantly upregulated in LUAD and PAH. In addition, we discovered a significant difference in infiltration for most immune cells between high-and low-G6PD expression groups. The mRNA and protein expressions of G6PD were significantly upregulated in LUAD and PAH. G6PD knockdown decreased proliferation, cloning, and migration of A549 cells and cell proliferation in HPASMCs. We screened five potential drug molecules against G6PD and targeted glutaraldehyde by molecular docking. Conclusions: This study reveals that G6PD is an immune-related biomarker and a possible therapeutic target for LUAD and PAH patients.

show abstract

Section: Introductionmentioning

confidence: 99%

G6PD is a prognostic biomarker correlated with immune infiltrates in lung adenocarcinoma and pulmonary arterial hypertension

Ding,

Sang,

et al. 2024

Aging

View full text Add to dashboard Cite

show abstract

“…Proper risk stratification before major pulmonary surgery is essential to a smooth postoperative outcome. Cardiac hemodynamics evaluation is indispensable in this patient population and can predict postoperative mortality and morbidity depending on the extent of resection 1 , 2 , 3 ; however, the impact of pulmonary hypertension (PH) is often overlooked and almost never properly evaluated. The National Emphysema Treatment Trial highlighted the importance of PH in the mortality and morbidity of patients undergoing lung volume–reduction surgery, going as far as establishing PH as a contraindication to surgery.…”

mentioning

confidence: 99%